|
Mar 8
|
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
|
|
Dec 12
|
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
|
|
Dec 7
|
ALLR: Stenoparib Clinical Update
|
|
Dec 5
|
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
|